2019 HIV & HBV Cure Forum
20 & 21 July 2019 | Mexico City, Mexico

In 2019, the IAS Towards an HIV Cure initiative, in collaboration with the International Coalition to Eliminate Hepatitis B (ICE-HBV), will organize a 1.5 day HIV & HBV Cure Forum on 20 & 21 July 2019, immediately preceding the 10th IAS Conference on HIV Science (IAS 2019).

Following the success of the 2017 HIV Cure & Cancer Forum, the 2019 Forum will focus specifically on the intersection between the scientific efforts in hepatitis B (HBV) and HIV cure research, and seek to merge these two disciplines to accelerate the pace of discovery in cure research for the two fields.

The Forum co-chairs represent an international cohort of experts in the HIV and HBV cure fields:

  • Dr. Steven Deeks, Professor of Medicine at the University of California, San Francisco (UCSF), United States
  • Prof. Anna Kramvis, Director of the Hepatitis Virus Diversity Research Unit at the University of Witwatersrand, South Africa
  • Prof. Sharon Lewin, Director of the Doherty Institute for Infection and Immunity, University of Melbourne, Australia
  • Prof. Seng Gee Lim, Director of Hepatology at the National University Health System, Singapore

Forum Objectives

  • Accelerate research on similar curative strategies being tested in both domains;
  • Create an environment to foster collaborations and merge the HIV cure and HBV cure disciplines;
  • Provide an opportunity for the next generation of investigators to launch their careers through interaction and discussion with peers;
  • Promote increased investments in cure research;
  • Provide a platform for information sharing, debate and network among peers.
  • Day 1
  • Day 2
  • Poster Exhibition

Day 1

The abstracts presented at the 2019 HIV & HBV Cure Forum are published in a supplement of the Journal of Virus Eradication and can be found in the abstract portal here.

All photos from day 1 can be accessed here.

Opening Session

Keynote Address: Hepatitis B virus: an ancient curse and the modern blessing for its cure

Jake Liang, NIH Intramural Research Program, United States

Presentation

Session 1: Biomarkers of cure: Understanding persistence

Invited Speaker: Measuring the HIV reservoir: Insights from single cell analyses

Lillian Cohn, Chan Zuckerberg Biohub, United States

Presentation

Invited Speaker: HBV cure therapies: How do we measure success?

John Tavis, St. Louis University School of Medicine, United States

Presentation

OA1-1: Clonal integration site expansion of infected cells is a main contributor of HIV persistence in more differentiated T cell subsets during suppressive ART

Jori Symons, The Peter Doherty Institute for Infection and Immunity, The University of Melbourne and Royal Melbourne Hospital, Australia

Presentation

OA1-2: Longitudinal proviral sequencing provides a window into selection pressures exerted on infected cells and provides an upper bound estimate of proviral half-lives which are influenced by expression and splicing potential

Una O'Doherty, University of Pennsylvania, United States

Presentation

OA1-3: Immune activation markers associated with levels and diversity of intact HIV proviruses during HIV-HBV co-infection

Ciccy Xiao Qian Wang, The Westmead Institute for Medical Research and Sydney Medical School-Westmead, University of Sydney, Australia

Presentation

Session 2: Role of Antivirals in Cure

Invited Speaker: Why think about antiretrovirals and eradication?

Daria Hazuda, Merck & Inc., United States

Presentation

Invited Speaker: Can HBV be cured by antiviral therapy alone?

Massimo Levrero, Hepato-Gastroenterology, Hospice Civils de Lyon and INSERM U1052 – Cancer Research Center of Lyon (CRCL), France

Presentation

Flash Talk: Effects of siRNA on hepatitis B infection

Man Fung Yuen, The University of Hong Kong, Hong Kong

Presentation

Session 3: Gene Therapy

Invited Speaker : Status and update of HIV gene therapy clinical trials

Pablo Tebas, Perelman School of Medicine, University of Pennsylvania, United States Presentation

Presentation

Invited Speaker : The prospects of curing chronic HBV infection using gene therapy

Patrick Arbuthnot, University of the Witwatersrand, South Africa

Presentation

Panel Discussion: Achieving a cure for HIV & HBV: Beyond the science

Daria Hazuda, Merck & Inc., United States

Massimo Levrero, Hepato-Gastroenterology, Hospice Civils de Lyon and INSERM U1052 – Cancer Research Center of Lyon (CRCL), France

Moses ‘Supercharger’ Nsubuga, Stigmaless, Uganda

Eileen Scully, Johns Hopkins University, United States

Jeremy Sugarman, Johns Hopkins University, United States

Jan van Lunzen, ViiV Healthcare, United Kingdom

Day 2

The abstracts presented at the 2019 HIV & HBV Cure Forum are published in a supplement of the Journal of Virus Eradication and can be found in the abstract portal here.

All photos from day 1 can be accessed here.

Session 5: Immunotherapy: Vaccines and Antibodies

Invited Speaker: Broadly neutralizing antibodies as components of an HIV cure strategy

Katherine J Bar, Perelman School of Medicine, University of Pennsylvania, United States

Presentation

Invited Speaker: Restoring or replacing adaptive immunity in hepatitis B

Mala Maini, University College London, United Kingdom

Presentation

OA5-1: Tandem bispecific antibody prevents fully and induces prolonged T cell immunity against pathogenic SHIV in monkey models

Mengyue Niu, AIDS Institute, The University of Hong Kong, China

Presentation

Flash Talk: Ad26 & MVA therapeutic vaccines in acutely treated HIV: safety, immunogenicity, and effect on viral rebound

Donn Colby, Thai Red Cross AIDS Research Center, Thailand

Presentation

Flash Talk: Multiscale imaging of therapeutic antibody distribution and localization

Thomas J. Hope, Feinberg School of Medicine, Northwestern University, United States

Presentation

Session 6: Immunotherapy: Immune-Modifying Agents

Invited Speaker: Engineered immune-mobilising monoclonal T cell receptors against viruses

Lucy Dorrell, University of Oxford, United Kingdom

Presentation

Invited Speaker: Immunomodulatory approaches for HBV cure

Massimo Levrero, Hepato-Gastroenterology, Hospice Civils de Lyon and INSERM U1052 – Cancer Research Center of Lyon (CRCL), France

Presentation to follow

OA6-1: Targeting HIV/SIV Infection of CD4+ T Follicular Helper (Tfh) Cells: BCL6 Inhibition Represses HIV Infection CD4+ T Cells and Reduces Germinal Center Hyperplasia in Rhesus Macaque

Yanhui Cai, The Wistar Institute, United States

Presentation

OA6-2: Fingolimod treatment at ART initiation delays SIV rebound after ART interruption

Maria Pino, Yerkes National Primate Research Center, Emory University, United States

Presentation

OA6-3: Vesatolimod (GS-9620) is safe and pharmacodynamically active in HIV-infected individuals

Sharon Riddler, University of Pittsburgh School of Medicine, United States

Presentation

Closing Session

Closing Lecture: Disruptive Discoveries for HBV treatment and eradication

Raymond Schinazi, Emory University School of Medicine, United States

Presentation

IAS/Abivax Research-for-Cure Academy Fellowship Prize

Presentation

Highlights and next steps from the Sunnylands Summit: The Path Towards Ending HIV

Sharon Lewin, the Doherty Institute, The University of Melbourne, Australia

Presentation

Poster Exhibition

The abstracts presented at the 2019 HIV & HBV Cure Forum are published in a supplement of the Journal of Virus Eradication and can be found in the abstract portal here.

All photos from the forum can be accessed here.

P1: Reduced immune activation and low inflammatory monocyte frequencies during pregnancy are associated with preterm delivery

N. Mdletshe, C. Thobakgale, T. Malaba, L. Myer, C. Gray, M. Altfeld, M.-L. Newell, T. Ndung’u, Prematurity Immunology and HIV-infected mothers and their infants Study (PIMS)

South Africa

Poster available soon

P2: Phenotype and functionality of CD8+ T-cells before and after cART are related to the viral reservoir size in HIV infected subjects

Czernikier, J. Salido, C. Trifone, M.I. Figueroa, H. Salomón, P. Cahn, O. Sued, N. Laufer, Y. Ghiglione, G. Turk

Argentina

Poster available soon

P3: Early skewed differentiation and PD-1 expression in CD4+ T-cells relate to immune dysfunction and viral persistence in HIV+subjects one year post-cART initiation

J. Salido, A. Czernikier, C. Trifone, M.I. Figueroa, H. Salomón, P. Cahn, O. Sued, N. Laufer, Y. Ghiglione, G. Turk

Argentina

Poster available soon

P4: Nef genotype influences immune control in HIV-1 infected individuals carrying protective alleles

F. Method Mwimanzi, I. Ngare, M. Mori, J. Mann, P. Goulder, T. Ndung'u, T. Ueno

Japan

Poster available soon

P5: CD4+ T-cells expressing negative checkpoint receptors are associated with decreased mitochondrial oxidative phosphorylation in chronic HIV

L.M. Gangcuangco, C. Shikuma, B. Mitchell, S. Bowler, G. Chew, L. Ndhlovu, K. Kallianpur, M. Gerschenson, S. Souza, D. Chow

Philippines

Poster available soon

P6: Immune Activation Is Associated With Poor CD4 Reconstitution - A Study from South India

S. Saravanan, B. Kausalya, T. Dinesha, J. Boobalan, S. Sivamalar, S. Gomathi, A. Pradeep, S. Solomon, D. Smith, K. Murugavel

India

Poster available soon

P7: Relevance of Reg3α and I-FABP on microbial translocation, inflammation and reservoir size in people living with HIV

S. Isnard, R. Ramendra, F.P. Dupuy, V. Mehraj, J. Lin, N. Kokinov, B. Lebouché, C. Costiniuk, P. Ancuta, N.F. Bernard, M. Durand, C. Tremblay, J.-P. Routy, Montréal Primary HIV-infection study group, Canadian HIV and Aging cohort, and Canadian HIV infected slow progressors study

Canada

Poster available soon

P8: Persistent elevation of Tim-3 and PD-1 on memory T cells despite early ART initiation during primary HIV infection

G.E. Martin, M. Pace, J. Meyerowitz, J.P. Thornhill, J. Lwanga, H. Lewis, T. Solano, R. Bull, J. Fox, N. Nwokolo, S. Fidler, C.B. Willberg, J. Frater, CHERUB investigators

United Kingdom

Poster available soon

P9: Extracellular vesicles and their microRNA contents are biomarkers of HIV-1 disease progression

W.W. Bazié, J. Vitry, J. Boucher, E. Côté, S. Trottier, C. Gilbert

Burkina Faso

Poster available soon

P10: Tissue-specific effects of latency reversing agents on HIV transcriptional blocks in gut & blood

S. Telwatte, P. Kim, T.-H. Chen, J. Milush1, M. Somsouk, P. Hunt, S. Deeks, J. Wong, S. Yukl

United States

Poster available soon

P11: Different HIV Transcriptional Profiles in Memory CD4+ T Cells Subsets during ART

M.J. Ruiz, J. Plantin, A. Pagliuzza, M. Massanella, R. Fromentin, J.-P. Routy, N. Chomont

Canada

Poster available soon

P12: In-depth transcription profile comparison of multiple primary cell HIV latency models

S. Moron-Lopez, I. Sarabia, E. Battivelli, M. Montano, S. Telwatte, A. Bosque, E. Verdin, W. Greene, J.K. Wong, S.A. Yukl

United States

Poster available soon

P13: Hormonal control of HIV-1 latency by estrogen imparts gender-specific restrictions on the latent reservoir

J. Karn, C. Dobrowolski, S. Valadkhan, P. Wille, R. Hoh, M. Ghandi, S. Deeks, E. Scully

United States

Poster available soon

P14: Cell-associated HIV RNA and the ratio of HIV RNA to DNA have circadian cycles in HIV-positive individuals on antiretoviral therapy

J. Stern, M. Roche, A. Solomon, A. Dantanarayana, A. Reynaldi, M. Davenport, S.G. Deeks, W. Hartogenesis, F.M. Hecht, L. Cockerham, S.R. Lewin

Australia

Poster available soon

P15: Cellular modulation and HIV reactivation in response to serial treatment of latently HIV infected CD4 T cells with Histone Deacetylase inhibitors (HDACi)

J. Maxwell, A. Nefedov, C. Dorfmeier, G. Wu, Y. Li, P. Zuck, D. Hazuda, A. Webber, R. Barnard, B. Howell

United States

Poster available soon

P16: Galectin-1 promotes HIV-1 latency reactivation

J. Rubione, G. Duette, P. Perez, P. Pereyra Gerber, J. Salido, A. Cagnoni, L. Guzman, A. Adamczyk, O. Sued, Y. Ghiglione, N. Laufer, K. Mariño, G. Rabinovich, M. Ostrowski

Argentina

Poster available soon

P17: Cellular proliferation maintains genetically intact and defective HIV-1 over time

B Horsburgh, B. Hiener, J.-S. Eden, E. Lee, T. Schlub, S. von Stockenstrom, L. Odevall, J. Milush, T. Liegler, R. Hoh, R. Fromentin, N. Chomont, S. Deeks, F. Hecht, S. Palmer

Australia

Poster available soon

P18: The CARMA study - children on early suppressive therapy: total HIV-1 DNA quantitation 12 years post ART initiation

C. Foster, S. Dominguez, A. Tagarro, E. Nastouli, P. Palma, R. Gkouleli, J. Heaney, C. Giaquinto, P. Rossi, P. Rojo, EPIICAL

Spain

P19: CD32+CD4+ T cells are highly enriched in HIV DNA

A.Pasternak, G. Darcis, N. Kootstra, B. Hooibrink, T. van Montfort, K. Groen, S. Jurriaans, M. Bakker, C. van Lint, B. Berkhout

The Netherlands

Poster available soon

P20: Kansui, an Ingenol-Containing Herbal Supplement, Safely Induced CD8, NK, and Monocyte Activation in Three ART-Suppressed SIVmac251-Infected Rhesus Macaques

S. Lee, K. Kesmy, P. Bacchetti, R. Hoh, J. Lifson, D. Cary, B. Peterlin, S. Deeks, D. Hartigan-O'Connor

United States

Poster available soon

P21: Large in vivo expansion and subsequent partial contraction of a T-cell clone carrying a defective HIV genome reflect the dynamics of the HIV reservoir during ART

R. Fromentin, M. Massanella, C. Vandergeeten, V. Morcilla, W.W. Chiu, D. Looney, M. Ramgopal, D.D. Richman, L. Trautmann, S. Palmer, N. Chomont

Canada

Poster available soon

P22: Different regimens of Romidepsin administration for reversion of SIV latency in a rhesus macaque model of complete virus control

A. Kleinman, S. Murali Kilapandal Venkatraman, E. Penn, B. Policicchio, P. Sette, E. Brocca-Cofano, M. Cottrell, R. Sivanandham, A. Valentine, C. Xu, K. Raehtz, T. Dunsmore, G. Haret-Richter, A. Kashuba, J. Mellors, I. Pandrea, C. Apetrei

United States

Poster available soon

P23: Human Endogenous Retrovirus expression landscape in models of HIV-1 latency

M. de Mulder Rougvie, G. Beckerle, M. Bendall, L.P. Iniguez, D. Nixon

United States

Poster available soon

P24: The SMAC mimetic AZD5582 reverses HIV latency as a single agent in resting primary CD4+ T Cells

G. Sampey, D. Irlbeck, E. Browne, M. Kanke, E. Cule, S. Wills, S. Falcinelli, Z. Wang, J. Kircherr, B. Allard, E. Stuelke, K. Sholtis, R. Ferris, J. Brehm, D. Favre, J.-P. Routy, C. Jones, N. Archin, D. Margolis, R. Dunham

United States

Poster available soon

P25: Development of Cytotoxic Enhancing Agents (CEAs) to improve Shock-and-Kill strategies

T. Zaikos, R. Durga, S.-H. Huang, R. Brad Jones, A. Bosque

United States

Poster available soon

P26: Sting agonist as a kick and kill agent to target the HIV reservoir

M. Mavigner, A.D. Brooks, A. Koblansky, C. Galardi, H. Madsen, D.M. Margolis, G. Silvestri, A. Chahroudi

United States

Poster available soon

P27: CD8 depletion plus signalling of the non-canonical NF-kB pathway reverses latency in SIV-infected, ART-suppressed rhesus macaques

M. Mavigner, A.D. Brooks, G.K. Tharp, C. Mattingly, N. Schoof, T.H. Vanderford, S.E. Bosinger, G.C. Sampey, C. Galardi, R.M. Dunham, D.M. Margolis, G. Silvestri, A. Chahroudi

United States

Poster available soon

P28: Discovery and mechanistic study of novel suppressors of post-integrated HIV expression from African natural products

C. Schonhofer, K. Andrae-Marobela, J. Yi1, A. Cochrane, A. Pagliuzza, B. Abegaz, R. Davis, N. Chomont, Z. Brumme, M. Brockman, I. Tietjen

Canada

P29: Sustained SHIV reactivation by N-803 in ART-treated CD8-depleted macaques

J.B. McBrien, D.G. Carnathan, E. White, J. Lifson, J.H. Lee, J.T. Safrit, M. Paiardini, A. Chahroudi, G. Silvestri

United States

Poster available soon

P30: Latency reactivating agents : impact on human macrophages physiology and susceptibility to HIV-1 infection

L. Hany, M.-O. Turmel, C. Barat, M. Ouellet, M.J. Tremblay

Canada

Poster available soon

P31: Lessons from the Research in Viral Eradication of Reservoirs (RIVER) study: impact of a therapeutic vaccine targeting conserved HIV epitopes on T cell function in treated primary infection

J. Kopycinski, H. Yang, E. Kim, W. Stohr, T. Hanke, J. Frater, S. Fidler, L. Dorrell, RIVER trial investigators

United Kingdom

Poster available soon

P32: Oral TLR7 Agonist Administration Induces an Immunostimulatory Response in SIV-Infected ART-Suppressed Infant Rhesus Macaques

K. Bricker, V. Obregon-Perko, J. Hesselgesser, A. Chahroudi

United States

Poster available soon

P33: Allogeneic Stem Cell Transplant in HIV-1 Infected Individuals; An update of the IciStem Consortium

A.M.J. Wensing, M. Salgado, M. Kwon, J.M. Eberhard, A. Saez-Cirion, J. Schulze zur Wiesch, G. Hütter, J. Badiola-González, A. Bandera, L. Barrett, R.K. Gupta, B.E. Jensen, J.H.E. Kuball, L. Martín Carbonero, M. Nabergoj, K. Raj, R. Saldaña-Moreno, G. Scarlatti, L. Vandekerckhove, J.L. Díez Martín, M. Nijhuis, J. Martínez-Picado, IciStem Consortium

The Netherlands

Poster available soon

P34: CRISPR/Cas9 targeting HIV-1 regulatory genes inactivates latent proviral DNA and prevents new infection in T cell culture with inhibition of viral escape

Y. Ophinni, M. Inoue, T. Kotaki, M. Kameoka, Y. Hayashi

Japan

Poster available soon

P35: Rapamycin immune tolerization enables gene transfer following subcutaneous delivery of AAV6 but not CD4-retargeted AAV6 vectors in AAV-seropositive rhesus macaques

K. Jerome, D. Stone, E. Kenkel, M. Tanaka, S. Wangari, J. Ahrens, H.D. Feelixge, A. Kumar, W. Obenza, C. Peterson, H.-P. Kiem, L. Stensland, R. Mumane, M.-L. Huang, M. Aubert, S.-L. Hu

United States

Poster available soon

P36: Preferential infection of α4β7+ CD4+ T cells in early acute HIV-1 infection

L. McKinnon, A. Tokarev, A. Pagliuzza, A. Sivro, E. Kroon, N. Chomchey, N. Phanuphak, A. Schuetz, M. Robb, J. Ananworanich, N. Chomont, D. Bolton, on behalf of the RV254/SEARCH010 study

Canada

Poster available soon

P37: High HIV viral burden persists in CXCR3+Tfh despite very early cART initiation

O. Baiyegunhi, J. Mann, T. Nkosi, J. Pansegrou, K. Dong, T. Ndungu, B. Walker, Z. Ndhlovu

South Africa

Poster available soon

P38: Immune-phenotypic characteristics associated with an effective acute-phase response predict a reduced amount of integrated HIV DNA in naïve CD4+ T-cells in patients treated during acute HIV infection

A. Camiro-Zuñiga, M.A. Najera-Avila, M.D.R. Jaramillo-Jante, L. Gibellini, S. De Biasi, M. Pinti, E. Bianchini, D. Lo Tartaro, A. Neroni, M. Nasi, C. Mussini, L.E. Soto-Ramírez, J.J. Calva, P.F. Belaunzarán-Zamudio, B. Crabtree-Ramirez, J.G. Sierra-Madero, C. Hernández-Leon4, J.L. Mosqueda-Gómez, S. Navarro-Álvarez, D. Scott-Algara, A. Cossarizza, S. Perez-Patrigeon

Mexico

Poster available soon

P39: HIV infection of hepatitis B virus (HBV)-infected hepatocytes increases CXCL10 production and is associated with liver fibrosis in HIV-HBV co-infected individuals

K.P. Singh, J.M. Zerbato, W. Zhao, S. Braat, C. Deleage, S. Tennakoon, H. Mason, A. Rhodes, A. Dantanarayana, A.N. Harman, J. Rhodes, J. Torresi, P. Revill, J. Estes, A. Avihingsanon, S.R. Lewin, J. Audsley

Australia

Poster available soon

P40: Hepatitis B Virus co-infection in Panama, evaluation of prevalence and factors associated with new HIV infections, period 2016-2017

J. Góndola, J. Castillo, O. Castillero, C. González, A. Moreno, O. Chavarría, A. Ortíz, J.M. Pascale, A. Martínez

Panama

Poster available soon

P41: Diagnostic of HIV, TB and Hepatitis using GeneXpert platform in Africa: challenges, lessons learnt and way forward in the era of the Sustainable Development Goal

J.D.D. Iragena, F. Jallow, F. Mosha, H. Lago

Congo

Poster available soon

P42: Inflammatory markers associated with mortality in HIV-positive individuals from Côte d’Ivoire: role of HIV-HBV co-infection

G.M. Kouame, A. Boyd, R. Affi, R. Moh, A. Badjé, D. Gabillard, J.-B. N'takpé, S.-P. Eholié, K. Lacombe, A. Inwoley, X. Anglaret, C. Danel, the ANRS 12136 Temprano study

Côte d'Ivoire

Poster available soon

P43: Efficacy and safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide as maintenance treatment of patients with HIV and HBV coinfection

Y.-S. Huang, C.-Y. Cheng, H.-Y. Sun, P.-L. Lu, C.-H. Lee, S.-H. Cheng, Y.-T. Lee, B.-H. Liou, C.-E. Liu, C.-J. Yang, H.-J. Tang, S.-P. Lin, M.-W. Ho, S.-H. Huang, H.-C. Tsai, C.-C. Hung, Taiwan HIV Study Group

China

Poster available soon

P44: No evidence of neuroaxonal injury following latency reversal with vorinostat and HIV-1 specific vaccination in the RIVER trial

J. Alagaratnam, W. Stohr, J. Toombes, H. Zetterberg, S. Pett, M. Nelson, S. Kinloch, A. Clarke, N. Nwokolo, M. Johnson, J. Fox, T. Hanke, J. Kopycinski, L. Dorrell, A. Babiker, J. Frater, A. Winston, S. Fidler, RIVER trial investigators

United Kingdom

Poster available soon

P45: The impact of vorinostat and AGS-004, a dendritic cell-based immunotherapy, on persistent HIV-1 Infection

C. Gay, J.D. Kuruc, S.D. Falcinelli, J. Warren, J.L. Kirchherr1, K. Sholtis, B. Allard, E. Stuelke, A. Gamble, A. Plachco, I. Tcherapanova, J.J. Eron, N. Goonetilleke, M. DeBenedette, C.A. Nicolette, N.M. Archin, D.M. Margolis

United States

Poster available soon

P46: How Do HIV Cure Trial Researchers Respond to an Embedded Social Science Study?

H. Peay, S. Isaacson, N. Ormsby, A. Corneli, R.J. Cadigan, G. Henderson

United States

Poster available soon

P47: Barriers and facilitators of open contests to promote community engagement in HIV cure research: a qualitative evaluation among trial participants and community members

Y. Zhao, H. Bao, S. Day, L. Li, A. Mathews, J.D. Tucker

United States

Poster available soon

P48: Transgender women’s perceptions of HIV cure research: Qualitative interviews with transgender women living with HIV in Baltimore, MD, United States

T. Poteat, K. Dubé, A. Aqil, D. Evans

United States

Poster available soon

P49: Patient perspectives of HIV cure

K. MacDonald, S. Gupta, M. Ott, G. Zimet

United States

Poster available soon

P50: How will eventual HIV cure impact prevention behavior?

M. Magnus, J. Kanyinda, C.A. Boone, T. Young, E. Sarkodie, R. Strange, N. Caballero-Suarez, J. Fenech, T. Villa, A. Castel

United States

Poster available soon

In collaboration with:

Supported by:

 

Download the Forum Materials